Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Toronto

$105,000.00

Determining the therapeutic potential of HLA-deficient human pluripotent stem cell-derived beta-like cells

EF 2020-21

Résumé
Diabetes affects 10% of Canadians and increases blood sugar levels, which causes kidney failure, blindness, and other diseases. Patients with diabetes must therefore take medications to control blood sugar levels, but many of these, like insulin injections, do not fully normalize blood sugar levels and negatively affect quality of life. Transplantation of the pancreas or pancreatic islets - the part of the pancreas that makes insulin- can restore normal blood sugar levels without monitoring or input from patients, and in this way is superior to common diabetes drugs. However, there are two major problems with transplantation: 1) there are not enough organs for all patients, and 2) patients must take immune suppressing drugs to prevent organ rejection. These drugs have many side effects, such as increasing the risk of heart disease, infections, and cancer. Using human pluripotent stem cells, which can develop into any organ in the body, we can now make islet-like cells in vitro. Like islets, these mini-organs produce insulin and can restore normal blood sugar levels in diabetic animals. However, unlike organs used for transplantation, stem cells can multiply endlessly in vitro and are not in limited supply. Therefore, islet-like cells could be a superior, widely accessible therapy for diabetes. However, immune suppressing drugs would still be needed to prevent rejection, which would increase the risk of dangerous side effects. Scientists have engineered modified stem cells that can potentially avoid immune rejection by genetically editing a group of proteins known as "HLA", transforming them into universal donor stem cells. This proposal will study whether these stem cells can be used to generate safer islet-like organs in vitro. I will focus on whether these HLA-deficient islet-like organs can effectively control blood sugar levels, and how well they can avoid rejection without immunosuppression. This work could lead to a novel and superior therapy for diabetes.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
439367
Name
Misra Paraish S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Determining the therapeutic potential of HLA-deficient human pluripotent stem cell-derived beta-like cells
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Allorejection; Cell Therapy; Diabetes Mellitus; Human Pluripotent Stem Cells; Transplantation
Abstract
Diabetes affects 10% of Canadians and increases blood sugar levels, which causes kidney failure, blindness, and other diseases. Patients with diabetes must therefore take medications to control blood sugar levels, but many of these, like insulin injections, do not fully normalize blood sugar levels and negatively affect quality of life. Transplantation of the pancreas or pancreatic islets - the part of the pancreas that makes insulin- can restore normal blood sugar levels without monitoring or input from patients, and in this way is superior to common diabetes drugs. However, there are two major problems with transplantation: 1) there are not enough organs for all patients, and 2) patients must take immune suppressing drugs to prevent organ rejection. These drugs have many side effects, such as increasing the risk of heart disease, infections, and cancer. Using human pluripotent stem cells, which can develop into any organ in the body, we can now make islet-like cells in vitro. Like islets, these mini-organs produce insulin and can restore normal blood sugar levels in diabetic animals. However, unlike organs used for transplantation, stem cells can multiply endlessly in vitro and are not in limited supply. Therefore, islet-like cells could be a superior, widely accessible therapy for diabetes. However, immune suppressing drugs would still be needed to prevent rejection, which would increase the risk of dangerous side effects. Scientists have engineered modified stem cells that can potentially avoid immune rejection by genetically editing a group of proteins known as "HLA", transforming them into universal donor stem cells. This proposal will study whether these stem cells can be used to generate safer islet-like organs in vitro. I will focus on whether these HLA-deficient islet-like organs can effectively control blood sugar levels, and how well they can avoid rejection without immunosuppression. This work could lead to a novel and superior therapy for diabetes.
Competitiondate
202011
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Misra, Paraish S
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~